Drug intelligence / Profile preview

EMP-123 (Allertein Therapeutics, LLC)

Development stage: Unknown
Lead developer: Allertein Therapeutics
Modality: Recombinant Proteins and Enzymes, Vaccines & Immunotherapeutics
Administration: Rectal

Overview

**EMP-123** is an investigational allergen-specific immunotherapy developed by Allertein for peanut allergy. It is a rectally administered suspension containing recombinant modified forms of the major peanut allergens Ara h 1, Ara h 2, and Ara h 3, with amino-acid substitutions intended to reduce IgE-binding, encapsulated in heat/phenol-killed *Escherichia coli*. In a completed Phase 1 study, rectal dose escalation produced frequent allergic reactions among peanut-allergic participants, including anaphylaxis; the program has not advanced beyond Phase 1 in identified public sources.

Targets

Ara h 2

Beyond the preview

Go deeper on EMP-123 (Allertein Therapeutics, LLC).

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on EMP-123 (Allertein Therapeutics, LLC).

Explore the full profile